Evidence map›Paper›PMID 40057934›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025

Voriconazole in the treatment of pediatric patients with hematologic malignancies and invasive fungal infections: a real-world study.

Namei Wu, Lili Cai, Qingquan Zhang, Yaxin Fan, Zhihang Lin

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Namei WuDepartment of Pharmacy, Fujian Medical University Affiliated First Quanzhou Hospital, Quanzhou, 362000, P. R. China.
Lili CaiDepartment of Pharmacy, Fujian Medical University Affiliated First Quanzhou Hospital, Quanzhou, 362000, P. R. China.
Qingquan ZhangDepartment of Pharmacy, Fujian Medical University Affiliated First Quanzhou Hospital, Quanzhou, 362000, P. R. China.
Yaxin FanInstitute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, 200040, P. R. China. fanyaxin@fudan.edu.cn.
Zhihang LinDepartment of Pharmacy, Fujian Medical University Affiliated First Quanzhou Hospital, Quanzhou, 362000, P. R. China. zhlin@fjmu.edu.cn.

Funding

Startup Fund for Scientific Research, Fujian Medical University 2021QH1243
6 · The paper itself

Abstract

purposeTo evaluate the factors influencing voriconazole (VRC) administration, clinical efficacy, and safety in children with hematological malignancies (HM) and invasive fungal infection (IFD).

methodsThis is a single-center, retrospective real-world study conducted between July 2018 and December 2023. Univariate and multivariate logistic regression analysis were used to analyze the affecting factors.

resultsA total of 167 patients were included in this study. Among them, 13.77% (23/167) of children under 2 years old received off-label use of VRC, with an initial maintenance dose higher than that of other groups (P < 0.001). There were 8 cases (4.79%) of cured, 148 cases (88.62%) of improved, and 11 cases (6.59%) of ineffective. Thirty-eight cases experienced adverse drug reactions (ADR), with a highest incidence (10.2%) of hepatotoxicity. The concomitant proton pump inhibitors (PPIs), days of central venous catheterization and coagulopathy were independent influencing factors of ADR. Sixty-six patients underwent therapeutic drug monitoring (TDM), which increased the probability of achieving the target plasma trough concentration (C

conclusionAttention to the off-label use of VRC in children < 2 years old, hypoalbuminemia and coagulopathy correction, potential drug interactions with VRC, and ADR monitoring is crucial for clinical efficacy and safety.

Indexed as

Antifungal AgentsHematologic NeoplasmsInvasive Fungal InfectionsVoriconazoleAdolescentChildChild, PreschoolDrug MonitoringFemaleHumansInfantMaleRetrospective StudiesTreatment OutcomeAntifungal AgentsVoriconazoleChildrenHematological malignanciesIndividualized medicationInvasive fungal diseaseTherapeutic drug monitoringVoriconazole

Identifiers

PMID40057934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.